d4diddy, you claim to have had information regarding ASD interests.
For example, you write ASD is not interested in settling out of court for a paltry sum of MONEY. They believe CDEx is infringing on their patent claim and they want it stopped. That is the purpose of the suit.
You claim to know that ASD was not interested in settling out of court for a paltry sum of MONEY, so...why did ASDI settle out of court if that was NOT in their interest?
ASD's equipment (software by CAMO I think) is referenced here...
Why is it so difficult to find ASDI pharmaceutical products in the news? ValiMed products seem to be getting good press, where is the ASDI pill machine? Does it use CAMO?
Also of interest is the fact that the University of Michigan appears to have a number of EXCELLENT people involved in fluorescence related research.
For example...
Public release date: 22-Feb-2008 University of Michigan Health System
'Fluorescent' cells give early warning for eye disease A device that measures metabolic stress could help eye doctors diagnose disease before symptoms appear
Improving Medication Safety: Independent 18 Month Study of ValiMed™ Medication Validation System by CDEX Published in American Journal of Health-System Pharmacists
ValiMed™ detected five potentially serious medication errors while consistently validating the correct medication solutions during an 18 month study at a major University Hospital.
United States Patent 7,154,102 Poteet , et al. December 26, 2006
System and methods for detection and identification of chemical substances
The invention provides a system and method utilizing, among other things, fluorescence spectroscopy in the ultraviolet portion of the electromagnetic spectrum to determine chemical species and concentrations.
Inventors: Poteet; Wade Martin (Tucson, AZ), Marsteller; Laurence (Tuscon, AZ), Shriver; Timothy D. (Vail, AZ)
There are established software applications that can evaluate the potential interactions between known medications. There is, however, no measured in m.sup.2 technology available enabling a caregiver to efficiently identify unlabeled medications (and/or to evaluate potential interactions between several unidentified medications).
The output of the invention may be expressed as a probability or percentage chance of a drug interaction. The invention may include software that is either adjustable or institutionally designated (and therefore fixed) to trigger the invention's audible and/or visible drug interaction indicators (e.g., the drug interaction limits that correspond to the invention's green, yellow, amber and red lights).
d4diddy writes "The point is that ASD is not interested in settling out of court for a paltry sum of MONEY."
Well, if ASD WAS not interested in settling out of court for a paltry sum of MONEY, ASD was probably not too happy because it appears they settled.
Now today, just looking at patent info, it is difficult to determine how well the associated pharmacy products from ASD and CDEX are being received in the marketplace. Looking through recemt information provided by ASD and ValiMed clients, it seems ValiMed is performing better in my opinion.
Improving Medication Safety: Independent 18 Month Study of ValiMed™ Medication Validation System by CDEX Published in American Journal of Health-System Pharmacists ValiMed™ detected five potentially serious medication errors while consistently validating the correct medication solutions during an 18 month study at a major University Hospital.
U.S Federal District Court Dismisses ASD and CDEX Lawsuits with Prejudice
ROCKVILLE, MD.,– October 3, 2006- CDEX Inc. (OTCBB:CEXI) announced today that the U.S. Federal District Court in Denver, Colorado has reviewed and approved the Stipulation to Dismiss that was filed in the Court on September 29, 2006 as part of a settlement agreement reached between ASD and CDEX with regards to Civil Action No. 06-CV-426-RDB-CBS. Today, the Court entered an Order of Dismissal with Prejudice and vacated all pending actions before the Court. This action by the Court brings to a final end the patent infringement lawsuit that was filed by ASD against CDEX. It also brings to a final close CDEX’s counterclaims of invalidity and unenforceability that the company filed in response to ASD’s lawsuit.
“This case was settled in a manner that was fair and equitable to both parties, while preserving the company’s rights and protecting the interests of our shareholders” said, Jim Griffin, CDEX President and CEO.
I do not find much on ASDI pharmaceutical products being adopted or well accepted in the marketplace, but I do find ValiMed being adopted and well accepted. ASD seems to be focused on tablets now, and they also seem to depend upon a packaged software product per cross referencing CAMO. However, I cannot find much (at all) on ASDI pharmaceutical products being adopted or praised. Maybe I just didn't look hard enough. :-)
Hospitals with Contracts for Purchase or Lease of one or more CDEX ValiMed™ Medication Validation Systems (February 29, 2007)
All Children’s Hospital, Inc. (St. Petersburg, Florida) Children’s Hospitals and Clinics of Minnesota (Minneapolis, Minnesota) Children’s Hospitals and Clinics of Minnesota (St. Paul, Minnesota) Children’s Medical Center of Dallas (Dallas Texas) Cleveland Clinic Foundation (Cleveland, Ohio) Henry Ford Health System (Detroit, Michigan) Loyola University Medical Center (Maywood, Illinois) Mount Carmel Health System (Columbus, Ohio) Primary Children’s Medical Center (Salt Lake City, Utah) Stanford Hospitals and Clinics (Stanford, California) U.C. Davis Health System (Sacramento, California) University of Maryland Medical Center (Baltimore, Maryland) University of Michigan Health System (Ann Arbor, Michigan) University of Utah Hospitals and Clinics (Salt Lake City, Utah) Veterans Administration Hospital (Palo Alto, California) Children's Hospital of The King's Daughters (Norfolk, VA) Bronson Methodist Hospital (Kalamazoo, MI) East Jefferson General Hospital (Metairie, LA)
Press Release
CDEX Inc and London Imperial College Healthcare NHS Trust Announce Partnership Cooperation UK's first Academic Health Science Centre incorporating London’s St Mary's and Hammersmith Hospitals, in partnership with Imperial College London to test ValiMed™ in clinical pharmacy settings and engage in new product development.
Tucson, Arizona and London, England – January 23, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today a partnership cooperation with the Imperial College Healthcare NHS Trust in London to test ValiMed in the Hammersmith and Charing Cross hospitals and to work together in developing new medication signatures including chemotherapy and cytostatic drugs. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.
On January 7, 2008, CDEX announced publication of an 18 month independent study of the ValiMed™ Medication Validation System at the C.S. Mott Children's Hospital in the University of Michigan Health System in the American Journal of Health-System Pharmacists. “During the 18 months since [ValiMed] was implemented, five potentially serious medication errors have been detected and avoided,” the report stated. “[ValiMed] consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.” The press release from the University of Michigan can be accessed at http://www.ns.umich.edu/htdocs/releases/story.php?id=6255.
“We are delighted to have this opportunity to work in partnership with CDEX. By working in collaboration we will ensure product development is completely aligned with patient need to the mutual benefit of all,” said Professor Ann Jacklin, Chief Pharmacist at Hammersmith & Charing Cross hospitals, Imperial College Healthcare NHS Trust, and Visiting Professor at The School of Pharmacy University of London. In 2000 Ms. Jacklin initiated the formation of the Centre for Medicines Safety and Service Quality, a joint research centre between Hammersmith Hospital and the School of Pharmacy, and has been joint Chair of the centre since this time.
“We are honored that Professor Jacklin and her staff have elected to partner with CDEX in testing the ValiMed technology and developing new applications and signatures that will dramatically increase patient medications safety where it is most needed” said Malcolm Philips, CDEX President and CEO. “This marks another step in developing a global coalition of world class hospitals working together to address major medication delivery issues.”
News 
Market Data 
Discover 
